Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2022 10:30 ET | Source: G1 Therapeutics

G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal

RESEARCH TRIANGLE PARK, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it received Triangle Business Journal's...
May 18, 2022 10:15 ET | Source: G1 Therapeutics

G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference

RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive...
May 04, 2022 06:30 ET | Source: G1 Therapeutics

G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights

- Achieved $6.9 Million in Total Revenue in the First Quarter of 2022, Including $5.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Fully Deployed G1’s COSELA Sales Team as of...
May 02, 2022 17:30 ET | Source: G1 Therapeutics

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
April 21, 2022 08:30 ET | Source: G1 Therapeutics

G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022

RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
April 06, 2022 11:30 ET | Source: G1 Therapeutics

G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., April 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey and Raj Malik, M.D., G1’s...
April 01, 2022 16:15 ET | Source: G1 Therapeutics

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., April 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
March 31, 2022 16:05 ET | Source: G1 Therapeutics

New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Chemotherapy

RESEARCH TRIANGLE PARK, N.C., March 31, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results of a retrospective, observational...
March 01, 2022 17:00 ET | Source: G1 Therapeutics

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
March 01, 2022 11:15 ET | Source: G1 Therapeutics

G1 Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference and the 34th Annual Roth 2022 Conference

RESEARCH TRIANGLE PARK, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two...